How big is the UK TRT boom?

Why is there a private TRT boom at all?

Because the NHS treats testosterone deficiency as a disease state defined by laboratory thresholds, while a large population of symptomatic men sit above those thresholds. The private sector prices exactly that gap. NHS practice typically limits treatment to men with total testosterone below strict cut-offs — guidance commonly cited around 8 nmol/L, or somewhat higher where erectile dysfunction treatment is involved. The British Society for Sexual Medicine guidelines used across much of private practice work to a higher threshold, around 12 nmol/L, alongside symptoms. A man at 13 nmol/L with textbook symptoms can be declined by the NHS on the numbers and accepted privately on the numbers plus the symptoms. Neither decision is lawless; they are different clinical philosophies applied to the same blood test. This piece pairs with our analysis of the ADHD sector's year, because the two markets rhyme in ways regulators have plainly noticed.

Layer the pathway friction on top and the market writes itself. The NHS route runs GP consultation, morning bloods, repeat bloods, endocrinology referral and eventual initiation — realistically six to nine months from first visit to first treatment, where it proceeds at all. And it explicitly does not treat the "fine but wants to feel better" cohort. Private clinics compress that to weeks, with at-home blood testing, remote consultations and delivered medication. They will engage with the borderline and symptomatic cohort the NHS declines. Add the cultural tailwind — men's health content, fitness culture and social advertising normalising the conversation — and the demand side needs no further explanation.

What deserves more explanation than it usually gets is the supply side: none of this works without pharmacy. Testosterone is a prescription-only medicine and a controlled drug. Every one of those clinic models ends in a dispensing event. The architecture carrying that is the part of the boom this site exists to cover.

How does the TRT clinic model actually work?

It works as a paired structure. A clinical entity, typically registered with the Care Quality Commission (CQC), carries the doctors, consultations and prescribing decisions. A General Pharmaceutical Council (GPhC) registered pharmacy dispenses and delivers the medicine, either owned within the same group or contracted as a partner. Look at the credible operators' own compliance pages and the pattern is explicit: a CQC-registered provider for the clinical and prescribing function, and a named GPhC-registered pharmacy with its own superintendent for dispensing — sometimes separate companies within one group. It is the same architecture that carries medicinal cannabis and ADHD services. We anatomise it fully in our forthcoming piece on the clinic-plus-pharmacy model.

The patient journey the structure carries runs like this. Symptom questionnaire and at-home or clinic blood testing. Remote consultation with a General Medical Council (GMC) registered prescriber. Diagnosis against the clinic's threshold philosophy. Prescription of a testosterone preparation, then dispensing and tracked delivery by the pharmacy. Then the part that separates medicine from commerce: ongoing monitoring, with repeat bloods at defined intervals and dose adjusted against results and symptoms. The cycle runs indefinitely, because TRT is typically long-term therapy.

That last stage is also the economics. TRT is a subscription-shaped clinical service: recurring consultations, recurring bloods, recurring dispensing, low churn where the service is good. That is why the category has attracted serious operators and opportunists alike. It is also why adjacent expansion into weight-loss injections and broader men's health is already visible across the sector — comparison sites now score TRT and GLP-1 providers side by side like broadband deals.

What separates the credible clinics from the dangerous ones?

Monitoring, thresholds honestly applied, and the willingness to say no. The sector's own commentators are blunter about the spread than any regulator has yet been, describing a market containing excellent clinicians and frankly dangerous operators side by side. The failure pattern is consistent wherever it appears: prescription after a cursory questionnaire and a single low-friction consultation, no baseline rigour, no repeat bloods, no dose discipline. Treatment sold as a lifestyle product with a prescription attached.

The credible pattern is equally consistent, and it is worth stating as the checklist the market will eventually be held to:

The controlled drug status sharpens all of this. Testosterone is a Class C drug listed in Schedule 4 Part II of the Misuse of Drugs Regulations 2001. It is lawful to possess as a prescribed medicine and criminal to supply without authorisation, with penalties up to fourteen years. The illicit market — gym-sourced and web-imported product of unverifiable content — is both the sector's competitor and its cautionary backdrop. The legitimate sector's entire social licence rests on being visibly, structurally different from it. The full controlled drug picture for operators, including the import and personal-possession boundaries that trip patients and clinics alike, is the subject of our guide to testosterone as a controlled drug.

Where does the scrutiny arrive, and when?

It arrives through the same doors it used for ADHD services, and the sequence is already legible. First, the policy layer. The Department of Health and Social Care's call for evidence on private prescribing explicitly examines how patients access medicines through private routes, remote services included. TRT sits squarely inside that lens: a sector built entirely on private remote prescribing of a controlled drug should read that consultation as addressed to it. Second, the clinical regulators. The GMC expects the chosen medium of a remote consultation to support an adequate assessment, and the CQC has a pattern of attention to remote prescribing models. Both transfer directly from the ADHD precedent, where fully remote pathways that skipped required physical assessment triggered national reporting and local mandates within months. TRT's equivalents are obvious to anyone in the sector: baseline examination, cardiovascular and haematological monitoring discipline, and the treatment of borderline cases. Third, the advertising layer. A competitive market pushing testosterone content through social channels is one enforcement action away from a sector-wide chill. The prohibition on promoting POMs to the public does not care how the promotion is dressed.

Building above the minimum here means four things. The monitoring cadence evidenced per patient. The remote pathway's examination leg designed rather than waved through. The pharmacy relationship treated as governance. And marketing audited against the POM rule before someone else audits it for you. The operational standard for that first item — consultation, verification and monitoring for high-risk remote prescribing generally — is the subject of our forthcoming remote prescribing standards guide. It closes this series precisely because it is the piece every vertical shares.

Key takeaways

FAQs